{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016874","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.952081+00:00","generated_at":"2026-06-24T00:59:07.986557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca Q2 net loss $35.6M; cash $390.8M; pipeline on track for H2 catalysts","bullets":["Net loss of $35.6M ($0.30 per share) vs $28.2M ($1.20) year ago; R&D expenses $27.5M, G&A $8.4M.","Cash, equivalents, and marketable securities $390.8M as of June 30, 2022; expected to fund operations into H2 2024.","Initial Phase 1b monotherapy data for ERAS-007 (HERKULES-1) and Phase 1 data for ERAS-601 (FLAGSHP-1) expected H2 2022.","IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C-mutant NSCLC expected H2 2022.","Entered clinical trial collaboration with Eli Lilly to evaluate cetuximab + ERAS-601; expanded leadership and board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016874","json":"https://secwatch.observer/filing/0000950170-22-016874.json","markdown":"https://secwatch.observer/filing/0000950170-22-016874.md","text":"https://secwatch.observer/filing/0000950170-22-016874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/0000950170-22-016874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/eras-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:59:07.986557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}